Company intelligence / Profile preview
Novoron Bioscience
San Diego, California, United Statesnovoron.com ↗
- Ownership
- Private
- Employees
- ~17
- Development stage
- Preclinical
01
Overview
Novoron Bioscience develops first-in-class therapies targeting neurological repair, focusing on small molecule drugs that block prion-like protein spread to prevent neurodegeneration and enhance spinal cord regeneration. The company’s approach centers around modulating lipoprotein receptors for CNS repair. No published late-stage clinical results as of May 2025; programs are likely preclinical or IND-enabling.[1]
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesMulti-modality discovery (implied)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Novoron Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novoron Bioscience.